Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9- tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 20, 2005, Pages 5717-5732

  Seto, Shigeki ^a   Tanioka, Asao ^a   Ikeda, Makoto ^a   Izawa, Shigeru ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Effective bladder capacity; KRP 103; NK1 antagonist; Pyrimido 4,5 b 1,5 oxazocine

Indexed keywords

4,6 DICHLORO 2 (METHYLTHIO)PYRIMIDINE 5 CARBOXYLIC ACID; 6 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 2 METHYLTHIO 4 PHENYL 6,7,8,9 TETRAHYDRO 5H PYRIMIDO[4,5 B][1,5]OXAZOCIN 5 ONE; 6 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 4 (2 METHYLPHENYL) 2 METHYLTHIO 6,7,8,9 TETRAHYDRO 5H PYRIMIDO[4,5 B][1,5]OXAZOCIN 5 ONE; 6 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 4 CHLORO 2 METHYLTHIO 5,6,7,8 TETRAHYDROPYRIMIDO[5,4 F][1,4]OXAZEPIN 5 ONE; 6 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 4 CHLORO 2 METHYLTHIO 5,6,7,8,9,10 HEXAHYDROPYRIMIDO[4,5 B][1,5]OXAZOCIN 5 ONE; 6 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 4 CHLORO 2 METHYLTHIO 6,7,8,9 TETRAHYDRO 5H PYRIMIDO[4,5 B][1,5]OXAZOCIN 5 ONE; 6 [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 4 CHLORO 2 METHYLTHIO 6,7,8,9 TETRAHYDRO 5H PYRIMIDO[4,5 E][1,4]DIAZEPIN 5 ONE; NEUROKININ 1 RECEPTOR ANTAGONIST; OXAZOCINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER DISTENSION; BLADDER FUNCTION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GUINEA PIG; NONHUMAN;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; MAGNETIC RESONANCE SPECTROSCOPY; MUSCLE CONTRACTION; OXAZOCINES; RECEPTORS, NEUROKININ-1; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; URINARY BLADDER;

CAVIA; CAVIA PORCELLUS;

EID: 24344474075     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.06.015     Document Type: Article

References (36)

1. M.M. Chang, S.E. Leeman, and H.D. Niall Nat. New Biol. 232 1971 86 87
2. S. Guard, and S.P. Watson Neurochem. Int. 18 1991 149 165
3. U.S. Von Euler, and J.H. Gaddum J. Physiol. 72 1931 74 87
4. C.A. Maggi Gen. Pharmacol. 22 1991 1 24
5. A. Lecci, S. Giuliani, C. Garret, and C.A. Maggi Neuroscience 54 1993 827 837
6. M.C. Desai, S.L. Lefkowitz, P.F. Thadeio, K.P. Longo, and R.M. Snider J. Med. Chem. 35 1992 4911 4913
7. S. McLean, A. Ganong, P.A. Seymoir, R.M. Snider, M.C. Desai, T. Rosen, D.K. Bryce, K.P. Longo, L.S. Reynolds, G. Robinson, A.W. Schmidt, C. Siok, and J. Heym J. Pharmacol. Exp. Ther. 267 1993 472 479
8. M.C. Desai, L.A. Vincent, and J. Rizzi J. Med. Chem. 37 1994 4263 4266
9. T. Harrison, B.J. Williams, C.J. Swain, and R.G. Ball Bioorg. Med. Chem. Lett. 31 1994 2545 2550
10. M.S. Kramer, N. Cutler, J. Feighner, R. Shrivastava, J. Carman, J.J. Sramek, S.A. Reines, G. Liu, D. Snavely, E. W.-Knowles, J.J. Hale, S.G. Mills, M. MacCoss, C.J. Swain, T. Harrison, R.G. Hill, F. Hefti, E.M. Scolnick, M.A. Cascieri, G.G. Chicchi, S. Sadowski, A.R. Williams, L. Hewson, D. Smith, E.J. Carlson, R.J. Hargreaves, and N.M.J. Rupniak Science 281 1998 1640 1645
11. J.J. Hale, S.G. Mills, M. MacCoss, P.E. Finke, M.A. Cascieri, S. Sadowski, E. Ber, G.G. Chicchi, M. Kurts, J. Metzger, G. Eiermann, N.N. Tsou, F.D. Tattersall, N.M.J. Rupniak, A.R. Williams, Wayne Rycroft, R. Hargreaves, and D.E. MacIntyre J. Med. Chem. 41 1998 4607 4614
12. H. Natsugari, Y. Ikeura, Y. Kiyota, Y. Ishichi, T. Ishimaru, O. Saga, H. Shirafuji, T. Tanaka, I. Kamo, T. Doi, and M. Otsuka J. Med. Chem. 38 1995 3106 3120
13. Y. Ikeura, T. Tanaka, Y. Kiyota, S. Morimoto, M. Ogino, T. Ishimaru, I. Kamo, T. Doi, and H. Natsugari Chem. Pharm. Bull. 45 1997 1642 1652
14. Y. Ikeura, Y. Ishichi, T. Tanaka, A. Fujishima, M. Murabayashi, M. Kawada, T. Ishimaru, I. Kamo, T. Doi, and H. Natsugari J. Med. Chem. 41 1998 4232 4239
15. H. Natsugari, Y. Ikeura, I. Kamo, T. Ishimaru, Y. Ishichi, A. Fujishima, T. Tanaka, F. Kasahara, M. Kawada, and T. Doi J. Med. Chem. 42 1999 3982 3993
16. Y. Ishichi, Y. Ikeura, and H. Natsugari Tetrahedron 60 2004 4481 4490
17. C. Swain, and N.M. Rupniak J. Annu. Rep. Med. Chem. 34 1999 51 60
18. M. Gerspacher, and A. Von Sprecher Drugs Future 24 1999 883 892
19. Z. Gao, and N.P. Peet Curr. Med. Chem. 6 1999 375 388
20. T. Sakurada, C. Sakurada, K. Tan-No, and K. Kisara CNS Drugs 8 1997 436 447
21. S. Seto, A. Tanioka, M. Ikeda, and S. Izawa Bioorg. Med. Chem. Lett. 15 2005 1479 1484
22. S. Seto, A. Tanioka, M. Ikeda, and S. Izawa Bioorg. Med. Chem. Lett. 15 2005 1485 1488
23. C.J. Swain, M.A. Cascieri, A.P. Owens, W. Saari, S. Sadowski, C.D. Strader, M. Teall, M.B. Van Niel, and B.J. Williams Bioorg. Med. Chem. Lett. 4 1994 2161 2164
24. N.W. Gilman, P. Rosen, J.V. Earley, C. Cook, and L.J. Todaro J. Am. Chem. Soc. 112 1990 3969 3978
25. C.J. Swain, E.M. Seward, M.A. Cascieri, T.M. Fong, R. Herbert, D.E. MacIntyre, K.J. Merchant, S.N. Owen, A.P. Owens, V. Sabin, M. Teall, M.B. VanNiel, B.J. Williams, S. Sadowski, C. Strader, R.G. Ball, and R. Baker J. Med. Chem. 38 1995 4793 4805
26. J.A. Lowe III, S.E. Drozda, R.M. Snider, K.P. Longo, S.H. Zorn, J. Morrone, E.R. Jackson, S. McLean, D.K. Bryce, J. Borner, A. Nagahisa, Y. Kanai, O. Suga, and M. Tsuchiya J. Med. Chem. 35 1992 2591 2600
27. Yamada, K.; Matsuki, K.; Omori, K.; Kikkawa, K.; WO 2001083460; Chem. Abstr. 2001, 135, 357948.
28. S. Seto Tetrahedron Lett. 45 2004 8475
29. T. Sakamoto, Y. Kondo, and H. Yamanaka Chem. Pharm. Bull. 33 1985 4764
30. P. Rocca, C. Cochennec, F. Marsais, L. Thomas-dit-Dumont, M. Mallet, A. Godard, and G. Quéguiner J. Org. Chem. 58 1993 7832
31. J. Meisenheimer Ber. 59 1926 1848
32. S. Dion, P. D'Orleans-Juste, G. Drapeau, N.-E. Rhaleb, N. Rouissi, C. Tousignant, and D. Regoli Life Sci. 41 1987 2269 2278
33. O. Arunlakshana, and H.O. Schild Br. J. Pharmacol. 14 1959 48 58
34. J.S. Peterson, R.C. Hanson, and L. Noronha-Blob J. Pharmacol. Methods 21 1989 231 241
35. The study was carried out by Daiichi Pure Chemicals Co., Ltd.
36. 1H NMR spectrum of 3g showed an AB pattern for the benzylic and oxazocine ring methylene protons at room temperature. Each pair of methylene protons deteriorated to a very broad peak at 100°C and collapsed to one peak but with distinct fission patterns at 150°C. These results indicate that attempts to isolate the atropisomers about the oxazocine ring would give only racemic products due to rapid interconversion.